HUTCHMED (00013): Reached a licensing agreement with GlaxoSmithKline for KRAS-EGFR antibody-drug conjugates for cancer treatment.

HUTCHMED (00013) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and licensing agreement with a subsidiary of GSK plc (referred to as "GlaxoSmithKline"), granting the GSK subsidiary worldwide rights to develop and commercialize HMPL-A830, excluding mainland China, Hong Kong, Macau, and Taiwan. Clinical development will initially focus on indications for colorectal cancer, pancreatic cancer, and lung cancer. The agreement includes an upfront payment of $110 million and potential milestone payments for development, registration, and commercialization, totaling up to $1.295 billion, in addition to royalties based on net sales. This first-in-class antibody-drug conjugate (ADCC) candidate drug is composed of a highly selective and potent KRAS (Kirsten rat sarcoma) small molecule inhibitor as an active payload, conjugated with an anti-epidermal growth factor receptor (EGFR) antibody. The ADCC selectively targets tumor tissues through antibody guidance, enabling the potent cytotoxic payload to exert its effects. Colorectal cancer, lung cancer, and pancreatic cancer are the cancer types with the highest incidence of KRAS gene alterations, and patients often lack safe and durable KRAS therapies. HMPL-A830 aims to meet this need by delivering KRAS inhibitors directly to tumors expressing EGFR, while simultaneously blocking the EGFR and KRAS signaling pathways, thereby improving efficacy, durability, and tolerability. Under the terms of the agreement, Hutchmed Limited will be responsible for the global Phase I development program of HMPL-A830, which is expected to commence in the second half of 2026 (clinicaltrials.gov registration number: NCT07718581). The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of mainland China, Hong Kong, Macau, and Taiwan. Mr. Zheng Zefeng, acting CEO and CFO of HUTCHMED, said: "We are pleased to collaborate with GSK, a global leader in biopharmaceuticals, as both parties share the same vision of developing innovative cancer therapies to address significant unmet medical needs worldwide. Our ADCC combines the antibody with our patented small molecule inhibitor payload, thus achieving a dual mechanism of action. HMPL-A830 is the third candidate drug from our innovative payload platform, and it is the first candidate drug to be licensed to a global partner after the first two candidate drugs entered clinical development. This collaboration is a significant step toward maximizing the clinical potential of this drug and will usher in a new chapter in precision oncology." Dr. Hesham Abdullah, Senior Vice President and Head of Global Oncology R&D at GlaxoSmithKline, stated: "This collaboration reflects GlaxoSmithKline's increasing leadership in the oncology field and our firm commitment to advancing cutting-edge innovative therapies that benefit cancer patients. The dual-targeting mechanism of HMPL-A830, targeting both KRAS and EGFR, holds the promise of significantly improving current standard treatment regimens. We look forward to partnering with HUTCHMED to advance the development of this innovative drug."